Concepts (137)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lupus Erythematosus, Systemic | 21 | 2018 | 29 | 6.080 |
Why?
|
| Quality of Life | 11 | 2018 | 38 | 1.690 |
Why?
|
| Adult | 18 | 2018 | 759 | 1.210 |
Why?
|
| Middle Aged | 17 | 2018 | 756 | 1.140 |
Why?
|
| Female | 20 | 2018 | 1644 | 1.080 |
Why?
|
| Humans | 24 | 2019 | 2822 | 1.060 |
Why?
|
| Severity of Illness Index | 11 | 2018 | 97 | 1.010 |
Why?
|
| Patient Reported Outcome Measures | 4 | 2017 | 11 | 0.950 |
Why?
|
| Health Status | 4 | 2017 | 19 | 0.910 |
Why?
|
| Male | 16 | 2018 | 1781 | 0.890 |
Why?
|
| Surveys and Questionnaires | 7 | 2017 | 138 | 0.880 |
Why?
|
| Rheumatology | 2 | 2019 | 10 | 0.710 |
Why?
|
| Fatigue | 2 | 2018 | 9 | 0.700 |
Why?
|
| Antibodies, Antinuclear | 3 | 2017 | 5 | 0.630 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 19 | 0.600 |
Why?
|
| Lupus Nephritis | 1 | 2017 | 1 | 0.550 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 6 | 0.540 |
Why?
|
| Rheumatologists | 1 | 2017 | 8 | 0.540 |
Why?
|
| Unnecessary Procedures | 1 | 2017 | 5 | 0.540 |
Why?
|
| Biological Products | 1 | 2016 | 1 | 0.510 |
Why?
|
| Arthritis, Rheumatoid | 3 | 2019 | 24 | 0.480 |
Why?
|
| Pain | 4 | 2018 | 47 | 0.480 |
Why?
|
| Reproducibility of Results | 6 | 2017 | 80 | 0.460 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 4 | 0.440 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2014 | 2 | 0.440 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2014 | 2 | 0.440 |
Why?
|
| Interleukin-10 | 1 | 2014 | 4 | 0.440 |
Why?
|
| Interferon-alpha | 1 | 2014 | 5 | 0.440 |
Why?
|
| Interleukin-6 | 1 | 2014 | 19 | 0.430 |
Why?
|
| Psychometrics | 5 | 2017 | 26 | 0.410 |
Why?
|
| Cultural Characteristics | 1 | 2013 | 3 | 0.400 |
Why?
|
| Emotions | 3 | 2017 | 7 | 0.390 |
Why?
|
| Cross-Sectional Studies | 5 | 2017 | 100 | 0.320 |
Why?
|
| Aged | 4 | 2017 | 898 | 0.260 |
Why?
|
| Linear Models | 4 | 2018 | 34 | 0.250 |
Why?
|
| Self Report | 3 | 2017 | 19 | 0.250 |
Why?
|
| Body Image | 2 | 2017 | 3 | 0.250 |
Why?
|
| Young Adult | 3 | 2016 | 179 | 0.250 |
Why?
|
| Canada | 2 | 2016 | 7 | 0.240 |
Why?
|
| Clinical Trials as Topic | 2 | 2016 | 27 | 0.240 |
Why?
|
| Depressive Disorder | 2 | 2018 | 22 | 0.230 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 246 | 0.230 |
Why?
|
| Cross-Cultural Comparison | 2 | 2016 | 6 | 0.230 |
Why?
|
| Pre-Eclampsia | 1 | 2004 | 2 | 0.230 |
Why?
|
| Pregnancy Complications | 1 | 2004 | 5 | 0.230 |
Why?
|
| Chlamydia trachomatis | 1 | 2004 | 4 | 0.220 |
Why?
|
| Chlamydia Infections | 1 | 2004 | 5 | 0.220 |
Why?
|
| Predictive Value of Tests | 3 | 2017 | 48 | 0.220 |
Why?
|
| Treatment Outcome | 4 | 2016 | 182 | 0.220 |
Why?
|
| Adolescent | 2 | 2016 | 241 | 0.210 |
Why?
|
| Lupus Erythematosus, Discoid | 1 | 2004 | 1 | 0.210 |
Why?
|
| Pain Measurement | 4 | 2017 | 54 | 0.210 |
Why?
|
| Factor Analysis, Statistical | 3 | 2017 | 9 | 0.200 |
Why?
|
| Depression | 2 | 2013 | 57 | 0.180 |
Why?
|
| Stress, Psychological | 2 | 2018 | 23 | 0.170 |
Why?
|
| Time Factors | 2 | 2017 | 205 | 0.160 |
Why?
|
| Azacitidine | 1 | 2019 | 6 | 0.160 |
Why?
|
| Enzyme Inhibitors | 1 | 2019 | 37 | 0.150 |
Why?
|
| Mentors | 1 | 2019 | 8 | 0.150 |
Why?
|
| Arthritis, Experimental | 1 | 2019 | 23 | 0.150 |
Why?
|
| DNA Methylation | 1 | 2019 | 44 | 0.150 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 17 | 0.150 |
Why?
|
| Biomedical Research | 1 | 2019 | 12 | 0.150 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2018 | 33 | 0.150 |
Why?
|
| Teaching | 1 | 2019 | 14 | 0.150 |
Why?
|
| Faculty, Medical | 1 | 2019 | 27 | 0.150 |
Why?
|
| Chicago | 1 | 2018 | 148 | 0.140 |
Why?
|
| Mental Health | 1 | 2017 | 7 | 0.140 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2017 | 6 | 0.140 |
Why?
|
| Health Care Surveys | 1 | 2017 | 13 | 0.140 |
Why?
|
| Blood Sedimentation | 1 | 2017 | 14 | 0.140 |
Why?
|
| Illinois | 1 | 2017 | 21 | 0.140 |
Why?
|
| Philippines | 2 | 2017 | 3 | 0.130 |
Why?
|
| Sleep | 1 | 2017 | 49 | 0.130 |
Why?
|
| Health Status Disparities | 1 | 2017 | 6 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 47 | 0.120 |
Why?
|
| Software | 1 | 2015 | 8 | 0.120 |
Why?
|
| United States | 1 | 2016 | 231 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 82 | 0.120 |
Why?
|
| Physicians | 1 | 2015 | 15 | 0.120 |
Why?
|
| Critical Pathways | 1 | 2014 | 1 | 0.110 |
Why?
|
| Observational Studies as Topic | 1 | 2014 | 6 | 0.110 |
Why?
|
| Goals | 1 | 2014 | 6 | 0.110 |
Why?
|
| Language | 1 | 2014 | 13 | 0.110 |
Why?
|
| Interferon Regulatory Factors | 1 | 2013 | 1 | 0.100 |
Why?
|
| Interferon Type I | 1 | 2013 | 2 | 0.100 |
Why?
|
| Multiple Sclerosis | 1 | 2013 | 3 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 42 | 0.100 |
Why?
|
| Cognition | 1 | 2014 | 203 | 0.100 |
Why?
|
| California | 3 | 2017 | 13 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2011 | 222 | 0.070 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2008 | 8 | 0.070 |
Why?
|
| Arthralgia | 1 | 2008 | 25 | 0.070 |
Why?
|
| Osteoarthritis, Knee | 1 | 2008 | 48 | 0.070 |
Why?
|
| Pregnancy Outcome | 1 | 2004 | 4 | 0.060 |
Why?
|
| Hypertension | 1 | 2004 | 13 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2004 | 28 | 0.060 |
Why?
|
| Prevalence | 1 | 2004 | 39 | 0.060 |
Why?
|
| Comorbidity | 1 | 2004 | 48 | 0.060 |
Why?
|
| Pregnancy | 1 | 2004 | 49 | 0.060 |
Why?
|
| Lactones | 1 | 2004 | 1 | 0.060 |
Why?
|
| Methotrexate | 1 | 2004 | 1 | 0.060 |
Why?
|
| Sulfasalazine | 1 | 2004 | 1 | 0.060 |
Why?
|
| Sulfones | 1 | 2004 | 1 | 0.060 |
Why?
|
| Doxycycline | 1 | 2004 | 6 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2004 | 17 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2004 | 8 | 0.050 |
Why?
|
| Synovial Fluid | 1 | 2004 | 23 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 26 | 0.050 |
Why?
|
| Hydroxychloroquine | 1 | 2004 | 1 | 0.050 |
Why?
|
| Antirheumatic Agents | 1 | 2004 | 7 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2004 | 33 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2004 | 59 | 0.050 |
Why?
|
| Autoimmune Diseases | 1 | 2019 | 7 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2019 | 9 | 0.040 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2019 | 8 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2019 | 13 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2019 | 23 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 167 | 0.040 |
Why?
|
| Mice | 1 | 2019 | 305 | 0.040 |
Why?
|
| Social Class | 1 | 2017 | 7 | 0.030 |
Why?
|
| Japan | 1 | 2016 | 1 | 0.030 |
Why?
|
| Health Surveys | 1 | 2016 | 9 | 0.030 |
Why?
|
| Adaptation, Psychological | 1 | 2016 | 14 | 0.030 |
Why?
|
| Age Factors | 1 | 2016 | 84 | 0.030 |
Why?
|
| Australia | 1 | 2016 | 2 | 0.030 |
Why?
|
| Disabled Persons | 1 | 2016 | 9 | 0.030 |
Why?
|
| Animals | 1 | 2019 | 978 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2014 | 20 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2013 | 3 | 0.030 |
Why?
|
| DNA | 1 | 2013 | 24 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2013 | 61 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2013 | 28 | 0.030 |
Why?
|
| Mexican Americans | 1 | 2011 | 1 | 0.020 |
Why?
|
| Self Concept | 1 | 2010 | 5 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2008 | 26 | 0.020 |
Why?
|
| Knee Joint | 1 | 2008 | 39 | 0.020 |
Why?
|